Metformin use is associated with a decrease in the risk of hospitalization and mortality in COVID-19 patients with diabetes: A population-based study in Lombardy.

Luisa Ojeda-Fernández Andreana ForestaGiulia MacalusoPierluca Colacioppo Mauro Tettamanti Antonella ZambonStefano GenoveseIda FortinoOlivia Leoni Maria Carla Roncaglioni Marta Baviera

Published in: Diabetes, obesity & metabolism (2022)

In this large cohort, metformin use was associated with a protective effect in COVID-19 clinical outcomes, suggesting that it might be a potentially useful drug to prevent severe COVID-19 disease, although randomized controlled trials (RCTs) are needed to confirm this. While awaiting the results of RCTs, we suggest continuing prescribing metformin to COVID-19 patients with diabetes.

Keyphrases

coronavirus disease
sars cov
randomized controlled trial
primary care
respiratory syndrome coronavirus
cardiovascular events
cardiovascular disease
risk factors
drug induced
study protocol
meta analyses